Brian I Carr1, Petr Pancoska, Robert A Branch. 1. Liver Tumor Program, Kimmel Cancer Center,Thomas Jefferson University, Bluemle Building, Room 1002,233 S. 10th Street, Philadelphia 19107, PA, USA. brian.carr@jefferson.edu; brian.carr@kimmelcancercenter.org
Abstract
OBJECTIVES: 967 patients with unresectable and untransplantable, biopsy-proven hepatocellular carcinoma (HCC) were prospectively evaluated at baseline and followed up till death. Survival was the end point. RESULTS: We found that male gender, ascites, cirrhosis, portal vein thrombosis (PVT), elevated AFP or bilirubin, or alkaline phosphatase, were each statistically significant adverse prognostic factors. Patients with normal AFP survived longer than those with elevated AFP, even in the presence of PVT, large or bilobar tumors or cirrhosis. We used a bivariate analysis to separate patient sub groups based on liver function and tumor characteristics and found clear discrimination in survival between subsets; in addition both cirrhosis and presence of PVT were significant factors. We also used a purely mathematical approach to derive subgroups and a prognostic model for individual patients. Interestingly, the two approaches gave similar predictive information, which opens the possibility of a more detailed mathematical analysis in the future. The results of this large dataset show that amongst non-surgical HCC patients, there are clear subsets with longer survival. CONCLUSION: The data supports the concept of heterogeneity of HCC. The three factors, bilirubin, AFP, and PVT predominate in prognosis.
OBJECTIVES: 967 patients with unresectable and untransplantable, biopsy-proven hepatocellular carcinoma (HCC) were prospectively evaluated at baseline and followed up till death. Survival was the end point. RESULTS: We found that male gender, ascites, cirrhosis, portal vein thrombosis (PVT), elevated AFP or bilirubin, or alkaline phosphatase, were each statistically significant adverse prognostic factors. Patients with normal AFP survived longer than those with elevated AFP, even in the presence of PVT, large or bilobar tumors or cirrhosis. We used a bivariate analysis to separate patient sub groups based on liver function and tumor characteristics and found clear discrimination in survival between subsets; in addition both cirrhosis and presence of PVT were significant factors. We also used a purely mathematical approach to derive subgroups and a prognostic model for individual patients. Interestingly, the two approaches gave similar predictive information, which opens the possibility of a more detailed mathematical analysis in the future. The results of this large dataset show that amongst non-surgical HCC patients, there are clear subsets with longer survival. CONCLUSION: The data supports the concept of heterogeneity of HCC. The three factors, bilirubin, AFP, and PVT predominate in prognosis.
Authors: Terence C W Poon; Tai-Tung Yip; Anthony T C Chan; Christine Yip; Victor Yip; Tony S K Mok; Conrad C Y Lee; Thomas W T Leung; Stephen K W Ho; Philip J Johnson Journal: Clin Chem Date: 2003-05 Impact factor: 8.327
Authors: Sonia Pascual; Pedro Zapater; José Such; Antonio García-Herola; Laura Sempere; Javier Irurzun; José María Palazón; Fernando Carnicer; Miguel Pérez-Mateo Journal: Liver Int Date: 2006-08 Impact factor: 5.828
Authors: E Giannini; D Risso; F Botta; P Romagnoli; F Malfatti; A Fumagalli; E Testa; E Podestà; B Chiarbonello; S Polegato; R Testa Journal: J Intern Med Date: 2004-03 Impact factor: 8.989
Authors: Brian I Carr; Rosalba D'Alessandro; Maria G Refolo; Palma A Iacovazzi; Catia Lippolis; Caterina Messa; Aldo Cavallini; Mario Correale; Antonio Di Carlo Journal: J Cell Physiol Date: 2013-06 Impact factor: 6.384
Authors: Jeong Il Yu; Sang Min Yoon; Hee Chul Park; Jong Hoon Kim; Tae Hyun Kim; Joong-Won Park; Jinsil Seong; Ik Jae Lee; Hong Seok Jang; Chul Seung Kay; Chul Yong Kim; Eui Kyu Chie; Jin Hee Kim; Mi-Sook Kim; Young Min Choi Journal: Cancer Res Treat Date: 2014-07-16 Impact factor: 4.679